/Dexcom%20Inc%20HQ-by%20JHVEPhoto%20via%20Shutterstock.jpg)
With a market cap of $26.6 billion, DexCom, Inc. (DXCM) is a medical device company that designs, develops, and commercializes continuous glucose monitoring (CGM) systems for diabetes and metabolic health management in the United States and internationally. It offers products such as Dexcom G6, Dexcom G7, Dexcom ONE, and Stelo, serving patients, caregivers, and clinicians worldwide.
Shares of the medical device company have underperformed the broader market over the past 52 weeks. DXCM stock has declined 22.8% over this time frame, while the broader S&P 500 Index ($SPX) has gained 14.4%. However, the stock has risen 2.7% on a YTD basis, slightly outpacing SPX's 1.4% gain.